PAX3-FOXO1 dictates myogenic reprogramming and rhabdomyosarcoma identity in endothelial progenitors
-
Published:2023-11-15
Issue:1
Volume:14
Page:
-
ISSN:2041-1723
-
Container-title:Nature Communications
-
language:en
-
Short-container-title:Nat Commun
Author:
Searcy Madeline B., Larsen Randolph K., Stevens Bradley T., Zhang Yang, Jin Hongjian, Drummond Catherine J., Langdon Casey G.ORCID, Gadek Katherine E.ORCID, Vuong Kyna, Reed Kristin B.ORCID, Garcia Matthew R., Xu BeisiORCID, Kimbrough Darden W., Adkins Grace E., Djekidel NadhirORCID, Porter Shaina N., Schreiner Patrick A.ORCID, Pruett-Miller Shondra M.ORCID, Abraham Brian J.ORCID, Rehg Jerold E., Hatley Mark E.ORCID
Abstract
AbstractFusion-positive rhabdomyosarcoma (FP-RMS) driven by the expression of the PAX3-FOXO1 (P3F) fusion oncoprotein is an aggressive subtype of pediatric rhabdomyosarcoma. FP-RMS histologically resembles developing muscle yet occurs throughout the body in areas devoid of skeletal muscle highlighting that FP-RMS is not derived from an exclusively myogenic cell of origin. Here we demonstrate that P3F reprograms mouse and human endothelial progenitors to FP-RMS. We show that P3F expression in aP2-Cre expressing cells reprograms endothelial progenitors to functional myogenic stem cells capable of regenerating injured muscle fibers. Further, we describe a FP-RMS mouse model driven by P3F expression and Cdkn2a loss in endothelial cells. Additionally, we show that P3F expression in TP53-null human iPSCs blocks endothelial-directed differentiation and guides cells to become myogenic cells that form FP-RMS tumors in immunocompromised mice. Together these findings demonstrate that FP-RMS can originate from aberrant development of non-myogenic cells driven by P3F.
Funder
U.S. Department of Health & Human Services | NIH | National Cancer Institute Damon Runyon Cancer Research Foundation
Publisher
Springer Science and Business Media LLC
Subject
General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry,Multidisciplinary
Reference104 articles.
1. Skapek, S. X. et al. Rhabdomyosarcoma. Nat. Rev. Dis. Prim. 5, 1 (2019). 2. Kashi, V. P., Hatley, M. E. & Galindo, R. L. Probing for a deeper understanding of rhabdomyosarcoma: insights from complementary model systems. Nat. Rev. Cancer 15, 426–439 (2015). 3. Barr, F. G. et al. Rearrangement of the PAX3 paired box gene in the paediatric solid tumour alveolar rhabdomyosarcoma. Nat. Genet 3, 113–117 (1993). 4. Shapiro, D. N., Sublett, J. E., Li, B., Downing, J. R. & Naeve, C. W. Fusion of PAX3 to a member of the forkhead family of transcription factors in human alveolar rhabdomyosarcoma. Cancer Res. 53, 5108–5112 (1993). 5. Galili, N. et al. Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. Nat. Genet. 5, 230–235 (1993).
|
|